Combining the effect of thrombocytosis of thrombopoietin and interleukin-6 released by tumour cells, raised platelet counts (opposed to low or normal lymphocyte count) leads to increased PLR and hence worsened oncological outcome in patients as a negative predictor. Here, THPO is linked to thrombocytosis disease.